Blog
RSS FeedPosted by Michael Wonder on 13 Jun 2025
AbbVie’s Epkinly, Eisai’s Lenvima pass reimbursement review; Janssen’s Tecvayli fails
11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...
Posted by Michael Wonder on 13 Jun 2025
UCB's new psoriasis biologic Bimzelx debuts in Korea with reimbursement
13 June 2025 - Belgium-based UCB's novel psoriasis therapy, Bimzelx (bimekizumab), has officially entered Korea's competitive plaque psoriasis market with ...
Posted by Michael Wonder on 12 Jun 2025
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front
12 June 2025 - It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. ...
Posted by Michael Wonder on 06 Jun 2025
MSD Korea wins coverage boost for transplant infection drug Prevymis
4 June 2025 - MSD Korea has won expanded reimbursement for Prevymis (letermovir), extending coverage from 100 to 200 days ...
Posted by Michael Wonder on 03 Jun 2025
Ipsen’s Cabometyx kidney cancer reimbursement bid collapses in Korea after price talks fail
30 May 2025 - Ipsen Korea’s months-long effort to expand reimbursement for Cabometyx (cabozantinib) has ended in failure, cutting off ...
Posted by Michael Wonder on 08 May 2025
Lilly, Novo Nordisk seek insurance coverage in Korea for diabetes drugs Mounjaro and Ozempic
2 May 2025 - In Korea, Eli Lilly and Novo Nordisk are pushing for national health insurance coverage for their ...
Posted by Michael Wonder on 08 May 2025
Patient group urges quick reimbursement of Besremi for polycythemia vera
7 May 2025 - The Korea Leukemia Patients Organization has called for the reimbursement of Besremi (ropeginterferon alfa-2b), the only ...
Posted by Michael Wonder on 02 May 2025
Pfizer’s ALK lung cancer drug Lorviqua lands first-line reimbursement in Korea
2 May 2025 - Pfizer Korea has secured reimbursement for Lorviqua (lorlatinib) as a first-line treatment for ALK-positive metastatic non-small ...
Posted by Michael Wonder on 01 May 2025
AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer
22 April 2025 - AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for ...
Posted by Michael Wonder on 16 Apr 2025
Merck’s Tepmetko wins reimbursement in Korea after 3.5 years, expanding access for lung cancer patients with rare MET mutation
15 April 2025 - Merck’s targeted lung cancer therapy Tepmetko (tepotinib) has finally secured reimbursement from the National Health Insurance ...
Posted by Michael Wonder on 10 Apr 2025
Pfizer wins Korea nod for paediatric arthritis use of oral JAK inhibitor Xeljanz
7 April 2025 - Pfizer Korea has won national reimbursement for its oral JAK inhibitor Xeljanz (tofacitinib), expanding access to ...
Posted by Michael Wonder on 04 Apr 2025
Janssen Korea’s Zytiga secures expanded reimbursement for first-line prostate cancer treatment
2 April 2025 - Beginning in April, Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone as a ...
Posted by Michael Wonder on 03 Apr 2025
GSK Korea's long-acting HIV injection therapy gains insurance benefit
1 April 2025 - GSK Korea said its long-acting injectable HIV-1 combination treatment, Vocabria (cabotegravir 600 mg) and Rekambys (rilpivirine ...
Posted by Michael Wonder on 02 Apr 2025
Sanofi launches new cholesterol lowering injection in Korea with health insurance coverage
1 April 2025 - Sanofi Korea announced the launch of Praluent Pen 300 mg (alirocumab) today following its inclusion in ...
Posted by Michael Wonder on 20 Mar 2025
Global pharma gives up reimbursement in Korea, and this is a serious concern
19 March 2025 - "We believe convincing our headquarters is no longer feasible, and we have no plans to apply ...